secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001213900-25-009213
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed selects IVT formulation for INM-089 in dry AMD; preclinical data shows 10x safety margin
--------------------------------------------------------------------------------

- Selected intravitreal (IVT) formulation for INM-089 as drug candidate for dry age-related macular degeneration (AMD).
- Preclinical studies demonstrated successful delivery at doses up to 10 times projected therapeutic level, indicating favorable PK and safety margin.
- Completed dose-ranging in vivo studies to guide dose selection for pivotal preclinical toxicology studies.
- Intravitreal injection is established method for drug delivery to back of eye; overcomes challenges of topical formulations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025009213/0001213900-25-009213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025009213/ea0229633-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-009213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer